Combination drug therapy of the benign prostate hyperplasia

Abstract

Combination drug therapy (CDT) is the new modality of LUTS cause by the benign prostate hyperplasia. It means a combination of alpha-blockers and 5 alpha-reductase inhibitors.

The effect both drugs is different and complementary. Current evidence suggests that CDT should be considered in men with prostatic enlargement, elevated prostatic specific antigen level, lower urinary tract symptoms, and moderate or severe Brother

Keywords

• benign prostatic hyperplasia
• combination drug therapy